Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.88 Average Target Price from Analysts
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports ...
Hosted on MSN2d
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Travere Therapeutics (TVTX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...
Zacks.com on MSN3d
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Wall Street expects a year-over-year increase in earnings on higher revenues when Amicus Therapeutics (FOLD) reports results for the quarter ended December 2024. While this widely-known consensus ...
Herald4d
Noise Monitoring Panel: Govt rejects names proposed by Amicus Curiae
The government’s decision to reject the two names recommended by Amicus Curiae Adv Nigel de Costa Frias on the Noise Monitori ...
Live Law4d
Hema Committee Report: Amicus Curiae Tells Kerala High Court That An Eminent Woman Should Lead Formulation Of Film Policy
Advocate Mitha Sudhindran, appointed as Amicus Curiae by the special Bench hearing matters related to the Justice Hema ...
TD Cowen Reaffirms Their Buy Rating on Amicus (FOLD)
In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Amicus (FOLD – Research Report), with a price target of $20.00.